Kathryn H. Schmitz Answers: What Can Mouse Studies Offer Human Research?
Kathryn H. Schmitz, PhD, MPH, professor of Public Health Sciences and associate director of Population Sciences at the Penn State Cancer Institute, discusses benefits that can be reaped from running parallel mouse and human studies.
Kathryn H. Schmitz, PhD, MPH, professor of Public Health Sciences and associate director of Population Sciences at the Penn State Cancer Institute, discusses benefits that can be reaped from running parallel mouse and human studies.
Schmitz ran both a mouse model and human study to test different interventions that may prevent breast cancer recurrence and found that, while both types of trials have limitations, having the two happen side-by-side can address some of of these limitations. For example, in mouse studies, researchers were able to observe the animal all the way up to recurrence.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
